What senolytics are
Senolytics are compounds that selectively trigger death in senescent cells — damaged cells that stop dividing but resist apoptosis and keep secreting pro-inflammatory signals (the senescence-associated secretory phenotype, or SASP). The best-studied combination is the cancer drug dasatinib plus the flavonoid quercetin (often written “D+Q”); other candidates include fisetin and navitoclax-class drugs.
Why they matter for longevity
Senescent cells accumulate in ageing tissues and are thought to drive chronic “inflammaging.” In mice, intermittently clearing them improves physical function and extends healthspan, which is why senolytics are one of the most actively investigated geroscience approaches.
What the evidence shows
Most of the strongest data are still preclinical (cell and mouse studies), and machine-learning screens continue to surface new candidate molecules. Early human pilot trials — for example in older adults with mild cognitive impairment — are testing feasibility and biomarkers, not yet lifespan or hard clinical outcomes. We therefore rate the *longevity* claim Experimental: promising biology, no proven human benefit, and real drug-specific risks.
What to ask a clinic
Senolytics are not an approved anti-ageing therapy. If a clinic offers them, ask which exact drug and dose, under what medical supervision, what monitoring is in place, and what evidence they are relying on.